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Juvenile-onset systemic lupus erythematosus (JSLE) is a rare, heterogeneous
multisystem autoimmune disease that can affect any organ, and present with diverse
clinical and serological manifestations. Vasculitis can be a feature of JSLE. It more
commonly presents as cutaneous vasculitis than visceral vasculitis, which can affect the
central nervous system, peripheral nervous system, lungs, gut, kidneys, heart, and large
vessels. The incidence and prevalence of vasculitis in JSLE has not been well described
to date. Symptoms of vasculitis can be non-specific and overlap with other features
of JSLE, requiring careful consideration for the diagnosis to be achieved and promptly
treated. Biopsies are often required to make a definitive diagnosis and differentiate JSLE
related vasculitis from other manifestations of JSLE, vasculopathies, and JSLE related
antiphospholipid syndrome. Visceral vasculitis can be life threatening, and its presence
at the time of JSLE diagnosis is associated with permanent organ damage, which
further highlights the importance of prompt recognition and treatment. This review will
focus on the presentation, diagnosis, management and outcomes of vasculitis in JSLE,
highlighting gaps in the current evidence base.
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INTRODUCTION
Vasculitis is a well-recognized feature of juvenile-onset systemic lupus erythematosus (JSLE).
Despite this, there is a paucity of literature in this area. Vasculitis is defined by inflammatory
changes to vessel walls, affecting different types (arteries, veins, capillaries) and/or sizes of vessels
(large, medium, small) and a variety of sites (e.g., skin or visceral/internal organs). Symptoms
of JSLE-related vasculitis can be non-specific (e.g., fatigue, fever, weight loss) and overlap with
other features of the disease. Careful consideration is required to detect vasculitis, in particular
visceral vasculitis, which is less common but potentially life-threatening and requires prompt
and aggressive treatment. Histopathological assessment of tissue biopsies are the diagnostic gold
standard, but patients may be classified with “probable vasculitis” based on clinical features
alone (1). This review will update readers on literature available and highlight gaps in the
current evidence-base.
Vasculitis can be associated with disease flares in SLE (2–4), and is therefore integral part of
disease activity assessment tools, including the Systemic Lupus Activity Index (SLAM), British Isles
Lupus Assessment Group (BILAG), and Systemic Lupus Activity Assessment Index 2000 (SLEDAI)
(5). Patients with skin lesions that are not specific to SLE, such as cutaneous vasculitis, experience
significantly more active disease when compared to patients with lupus-specific skin lesions only
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(e.g., malar rash) (3). The presence of major organ vasculitis
at baseline influences the damage trajectory in JSLE patients,
and is associated with greater JSLE related permanent organ
damage (6).
CUTANEOUS VASCULITIS
Epidemiology
The exact prevalence of cutaneous vasculitis in JSLE is not
known. A study involving 179 patients with JSLE in the UK
found that 12% experienced cutaneous vasculitis (7). A Brazilian
study of 414 patients with SLE including 60 patients with JSLE
found that 21.6% of JSLE patients developed cutaneous vasculitis
compared with 15.4% of those with adult-onset disease (aSLE,
difference was not statistically significant) (8). A study involving
50 aSLE patients found individuals with cutaneous vasculitis to
be significantly younger when compared to patients who did not
develop vasculitis (26.5 vs. 30.3 years; p= 0.018) (9).
Associations With Other Organ
Manifestations of SLE
In aSLE cutaneous vasculitis has been shown to be associated
with lupus nephritis, hyopocomplementaemia (9, 10),
musculoskeletal, constitutional, cardiovascular manifestations
and Sjogren’s syndrome (9). In a further study involving 170
aSLE patients, patients with lupus nephritis were shown to be
at increased risk of cutaneous vasculitis (10). Lastly, cutaneous
vasculitis may also be associated with neuropsychiatric lupus in
aSLE (11, 12).
Clinical Presentation and Pathophysiology
In JSLE, skin manifestations can be divided into lupus-
specific (e.g., malar rash, discoid lupus, panniculitis) and lupus
non-specific, including cutaneous vasculitis. SLE-associated
cutaneous vasculitis affects small or medium-sized vessels in
the skin and subcutaneous tissues. It has a wide variety of
presentations that depend on the size of vessels involved and
the extent of the vasculature affected. Cutaneous vasculitis most
frequently affects the lower and upper limbs (13).
Vasculitis affecting the small vessels of the skin (arterioles,
capillaries, post-capillary venules in the superficial, and mid-
dermis) usually presents with petechiae, purpura, and/or
punctate vasculitis lesions. Petechiae are pinprick macules which
do not blanch and are not palpable, resulting from capillary
inflammation and red blood cell extravasation (Figure 1A) (14).
Purpura are caused by inflammation of venules and/or arterioles
and consist of larger papules and plaques which do not blanch
and become palpable as damage progresses (Figure 1B) (14).
Punctate vasculitic lesions, ulcerations and tissue necrosis are
caused by reduced perfusion; shallow ulcers are caused when
this affects the small vessels and deeper ulcers are caused when
medium-sized vessels are affected (Figure 1C).
Vasculitis of medium sized vessels in the dermis or
subcutaneous layers may cause livedo reticularis, nodules, and/or
the aforementioned deep ulcers (15). Livedo reticularis is a
small or widespread area of mottled, reticulated, reddish-purplish
discoloration of the skin caused by compromised blood flow in
FIGURE 1 | Skin manifestations in SLE and SLE-like disease. Small vessel
vasculitis is a “common” feature in SLE-associated skin vasculitis. (A) Petechia
and ecchymosis are the result of capillary inflammation and red blood cell
extravasation; (B) palpable purpura are caused by inflammatory damage to
venules and/or arterioles; (C) ulcerations and tissue necrosis are the result of
reduced perfusion; (D,E) chilblain lesions can manifest as chilblains (cold
induced sores) that may ulcerate, or painful and/or itchy bluish-reddish
discoloration with swelling; (F) vasculopathy and finger atrophy in a patient
with complement deficiency and secondary type I interferon upregulation.
the medium-sized vessels (15). Cutaneous ulcers, nodules, digital
gangrene, livedo racemosa, and pyoderma-gangrenosum-like
lesions are indicative of arterial involvement. Individuals affected
have higher probability of associated visceral vasculitis (16).
Lesions mimicking vasculitis can be caused by haemorrhagic and
vaso-occlusive disease (17).
Cutaneous vasculitis in JSLE is most commonly an immune-
complex mediated small-vessel vasculitis (18) (Figure 2).
Histological examination of lesions allows determination
of the size of vessel affected and immune cells driving
inflammation. Typical findings in lupus-related cutaneous
vasculitis are small (predominantly) and medium vessel (less
commonly) neutrophilic vasculitis with IgG, IgM and/or
complement deposition at the basement membrane zone on
direct immunofluorescence examination (14).
Urticarial Vasculitis
Urticarial vasculitis is a recognized rare presentation of SLE
presenting with hives lasting more than 24 h which may
be entirely asymptomatic, pruritic, or painful. It usually
resolves with hyperpigmentation or purpura (18, 20, 21).
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FIGURE 2 | Pro-inflammatory mechanisms in immune complex vasculitis. Immune complex vasculitis is not disease specific and can be a feature or leading symptom
of various disorders, including infections and autoimmune/inflammatory conditions. Immune complex deposition result in complement activation, which in turn
mediates local inflammation and oedema. This results in the recruitment of immune cells, including macrophages, neutrophils, and NK cells, which further contribute
to inflammation and tissue damage through inflammatory cytokine expression. Mast cell and basophil degranulation further amplifying tissue edema and mediates
vasodilation. Reproduced with permission from (19).
The incidence of JSLE-associated urticarial vasculitis is
unknown but there are several case reports (22–25). Urticarial
vasculitis is an immune-complex mediated small-vessel process
with leukocytoplastic changes on histology (14). The term
“hypocomplementemic urticarial vasculitis” describes the
coexistence of hypocomplementemia. Affected individuals
frequently exhibit anti-C1q antibodies, which may contribute to
altered immune complex processing and removal, and associated
systemic involvement (21, 26, 27).
Cryoglobulinaemic Vasculitis
Cutaneous vasculitis can present with cryoglobulinaemic
vasculitis, manifesting as purpuric lesions. IgM and C3
containing immune complexes are present on direct
immunofluorescence (Figure 2). Reports on cryoglobulinaemia
and vasculitis in children are limited (13, 28).
Diagnosis
The diagnosis of SLE-associated cutaneous vasculitis is based on
clinical assessment. However, where practical and in cases of
uncertainty, biopsies should be taken to confirm the diagnosis
(15). This is of particular importance because cutaneous
vasculitis can be a sign of high disease activity, and may trigger
escalation of treatment (3). A study in aSLE patients found
that while 36% of patients with digital lesions were clinically
diagnosed with vasculitis, following dermatological/histological
review only 4% actually had confirmed vasculitis (29). Timing,
location, and appropriate depth of biopsy are important for
diagnostic accuracy. Ideally, biopsies should be taken within 48 h
of the lesions appearing, to avoid false negative results (14).
Treatment
Topical and low-dose systemic corticosteroids, and/or
antimalarial agents (usually Hydroxychloroquine) are usually
considered first-line treatment for cutaneous vasculitis. More
severe disease may require high-dose steroids, intravenous
immunoglobulins (IVIG), plasmapheresis, and/or cytotoxic
treatments (18). Rituximab can be effective in some SLE patients
with otherwise treatment refractory cutaneous vasculitis (15).
VISCERAL VASCULITIS
Visceral vasculitis is present in approximately 6% of aSLE patients
(30). Reliable data on the prevalence in JSLE does not exist. It can
affect a number of organs including the central nervous system
(CNS), peripheral nervous system (PNS), lungs, gut, and more
rarely the kidneys, heart, and large abdominal and/or thoracic
vessels (1). Visceral vasculitis usually manifests in the context of
disease flares, and can coexist with cutaneous vasculitis (1).
CNS Vasculitis
In patients developing neuropsychiatric manifestations
of SLE, CNS vasculitis should be considered. However,
the contribution of CNS vasculitis in CNS lupus may be
limited (1). Indeed, other mechanisms including T-cell and
autoantibody-mediated damage to neuronal tissue underlie
the majority of neuropsychiatric manifestations (31, 32).
Historic postmortem studies estimated the incidence of CNS
vasculitis in SLE to be around 7–10% (33). In the context of
neuropsychiatric SLE it is particularly important to consider
the contribution of antiphospholipid syndrome (APS) (34). SLE
vasculitis and APS are the result of very different underlying
pathologies that may require differential treatment. APS leads
to thrombo-occlusive vasculopathy, warranting treatment with
anticoagulation (e.g., heparin) and/or anti-aggregation (e.g.,
apsirin, clopidogrel) and/or intensive immunosuppressive
therapy (e.g., corticosteroids, IVIG, rituximab or other
immunosuppressive therapy, plasma exchange) in the context
of catastrophic APS (35). Case management is informed by the
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overall clinical picture and laboratory parameters. While APS is
characterized by the presence of persistent moderate-high titers
of antiphospholipid antibodies associated with APS, SLE flares
with vasculitis are associated with leukopenia, anti-ds-DNA
antibodies and hypocomplementaemia (1).
Diagnosing CNS vasculitis requires a high index of suspicion,
a systematic multi-disciplinary approach to diagnostic evaluation
with MRI imaging playing a central role, and thorough exclusion
of the differential diagnoses. Investigations should be directed
at the exclusion of underlying conditions, including infections
(the most common causes of secondary CNS vasculitis),
drug-induced vasculitis, malignancy-associated vasculitis,
non-vasculitic inflammatory brain diseases, demyelinating
disorders, and antibody-mediated inflammatory brain diseases
(36). The recent European evidence-based recommendations for
diagnosis and treatment of JSLE (the SHARE initiative) imply
that the initial diagnostic work-up of patients with suspected
neuropsychiatric JSLE should be performed as in patients
without SLE, and lumbar puncture/cerebrospinal fluid analysis,
electroencephalogram, neuropsychological assessment of
cognitive function, ophthalmologist review, nerve conductional
studies, and MRI scanning should be considered. However,
SHARE did not provide specific recommendations for suspected
SLE CNS vasculitis, but highlighted that a MRI scan cannot
exclude neuropsychiatric lupus (37). Even with angiography,
false negative results are possible if the small vessels are
predominantly involved (38), and brain biopsy may be required
(1, 36, 39). Treatment usually involves high-dose glucocorticoids
and cyclophosphamide, and may include plasmapheresis and
IVIG (40).
Peripheral Nervous System
(PNS) Involvement
Peripheral neuropathies including mononeuritis multiplex
can be the result of vasculitis and ischemic damage in JSLE.
Mononeuritis multiplex is substantially more common in
aSLE, when compared to JSLE patients. It is characterized
clinically by symmetric, mild-to-moderately severe sensorimotor
polyneuropathy (39). Nerve biopsies usually unveil axonal
degeneration and/or depletion, which can be associated
with nonspecific vascular changes or chronic perivascular
inflammation. Occasionally, biopsies may show necrotising
vasculitis (41). As few as two cases of mononeuritis multiplex
have been described in JSLE patients to date (42, 43).
Other causes of mononeuritis multiplex in children include
Eosinophilic Granulomatosis with Polyangiitis (EGPA;
formerly known as Churg-Strauss syndrome), polyarteritis
nodosa, hypersensitivity/toxic vasculitides, diabetes mellitus,
and Tangier’s disease (an inborn error of metabolism) (43).
Treatment of PNS vasculitis in JSLE may involve high-dose
corticosteroids and cyclophosphamide, but is based upon aSLE
case series (43).
Pulmonary Vasculitis
Acute lupus pneumonitis and diffuse alveolar hemorrhage
(DAH) are the two most common pulmonary presentations
of vasculitis in SLE. Fortunately, both are relatively rare
[pneumonitis: 0–14% (44), DAH: 2–5.4% of aSLE patients
(45, 46)]. Reports on the prevalence in JSLE currently do
not exist. Both conditions may present with sudden-onset
dyspnea, cough, fever, and hypoxia. Main clinical differences
are pleuritic chest pain in acute lupus pneumonitis, and
blood stained sputum or haemoptysis in DAH (47). However,
none of these necessarily have to be present. Radiological
features of acute lupus pneumonitis on computed tomography
(CT) scan include an often bilateral diffuse acinar filling
pattern in the lower lobes, and frequently coexists with
pleural effusion in ∼50% of patients (48). In DAH, diffuse
alveolar opacities are characteristically seen on CT (Figure 3).
Diffusion capacity for carbon monoxide (DLCO) is usually
increased due to the increased availability of hemoglobin
within the alveoli (47). In both conditions, bronchoscopy and
bronchial alveolar lavage (BAL) are required (where the patient’s
condition allows it) to exclude infectious differential diagnoses
or confirm the diagnosis. In DAH, aspirated fluid is bloody
and microscopically red blood cells and haemosiderin-laden
macrophages are present (45). Occasionally, an open lung
biopsy may be needed to reach a diagnosis of acute lupus
pneumonitis, with pathological findings including capillaritis,
diffuse alveolar damage and necrosis, cellular infiltrates, hyaline
membranes, and sometimes alveolar hemorrhage (47). The
pathogenesis of both acute pulmonary pneumonitis and
DAH is incompletely understood, but thought to involve
deposition of immune complexes in the alveolar septae
and blood vessels, and activation of complement leading
to capillaritis, with immunohistological studies demonstrating
immune complexes which include anti-ds-DNA antibodies and
C3 (49) (Figure 2).
Treatment of both acute lupus pneumonitis and DAH is based
upon case reports and small case series. Early detection and
treatment initiation are crucial. Patients are usually treated with
broad-spectrum antibiotics, high-dose corticosteroids and/or
cyclophosphamide, and may need mechanical ventilation, IVIG
and potentially plasma exchange (46, 47, 50). Both conditions are
characterized by poor prognosis with associatedmortality rates of
∼50%. In those who survive, persistent interstitial infiltrates and
FIGURE 3 | Diffuse alveolar hemorrhage in a 16-year-old SLE patient.
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lung function abnormalities are frequently seen, with potential
for progression on to chronic interstitial pneumonitis (48).
Gastrointestinal Vasculitis
Gastrointestinal symptoms are not uncommon in JSLE patients
and may relate to either treatment-related side effects, infections
or JSLE disease activity. Lupus mesenteric vasculitis (LMV),
characteristically presents with the clinical picture of an “acute
abdomen” with sudden onset, diffuse and severe abdominal
pain which can be associated with nausea, rectal bleeding,
and vomiting (51). Of note, corticosteroids and/or other
immunosuppressive treatments may mask symptoms and result
in diagnostic and therapeutic delay. The estimated prevalence
of LMV ranges between 0.2 and 9.7% among aSLE patients,
making up for ∼29–65% of aSLE patients presenting with an
acute abdomen (51). In a Taiwanese study comparing aSLE and
JSLE patients presenting with acute abdominal pain, LMV was
the most common cause of admission in the JSLE patients.
Furthermore, LMV was significantly more prevalent in JSLE
patients when compared to the aSLE group [12/38 (31.6%) vs.
15/1081 (3.9%); p = 0.016], occurring in JSLE patients with
high disease activity (SLE disease activity index, SLEDAI scores
>8). Children were also found to be more likely to experience
recurrent episodes of LMV (39.1% vs. 14.8%; p = 0.009) (52). In
contrast to this study, other studies have reported LMV in JSLE
patients with low SLEDAI scores (53, 54).
Bowel ischemia secondary to LMV can result in perforation,
hemorrhage and high mortality rates of up to 50%. The
importance of early laparotomy was emphasized by a study
demonstrating significantly higher survival in patients who
underwent early intervention (0/33 deaths when laparotomy
was undertaken within 24–48 h vs. 10/11 when laparotomy was
performed after 48 h) (55). LMV most frequently affects the
superior mesenteric artery that supplies the ileum and jejunum
(80–85%), with the rectum less frequently affected (14%), and
gastric involvement being very uncommon (56). Abdominal CT
is a useful investigation for diagnosing LMV. It is characterized
by the presence of dilated bowels, target lesions (abnormal bowel
wall enhancement), comb signs (engorgement of mesenteric
vessels), bowel wall thickening, and ascites (57). Histology
may demonstrate arteritis, venulitis, immune complex, C3, and
fibrinogen deposition, inflammatory cell infiltration, necrosis,
and thrombosis of vessels affected (58). No randomized trials
are available investigating treatment and associated outcomes
in LMV. Currently, treatment involves “bowel rest,” intravenous
corticosteroids, and cyclophosphamide in severe cases (39, 53, 58,
59). Successful use of Rituximab has also been described in case
series (58).
Renal Vasculitis
The prevalence of renal vasculitis in JSLE has not been
investigated. In aSLE, vasculitic changes affecting the larger
arterioles and small kidney arteries may (rarely) accompany
proliferative lupus nephritis (60). Focal segmental necrotizing
glomerulonephritis with fibrinoid necrosis can be seen, and may
lead to rapidly progressive renal failure (61). In a Spanish study
evaluating the prevalence and clinical characteristics of vasculitis
in a cohort of 670 aSLE patients, 76/670 (11%) patients exhibited
any vasculitis, but “only” 2/76 (3%) experienced renal vasculitis
(13). Treatment of renal vasculitis in JSLE usually involves high-
dose corticosteroid and cyclophosphamide (39).
Cardiac Vasculitis
Cardiac involvement in JSLE typically comprises pericarditis,
cardiomegaly, valvulitis, and conduction abnormalities. SLE
is associated with an increase in coronary heart disease risk,
and a 50-fold increased risk of myocardial infarction (62).
Coronary artery vasculitis occurs in both JSLE and adult SLE,
but is rare across all age groups (63–66). Clinical differentiation
of “classical” coronary artery disease from coronary arteritis is
difficult and requires angiography. Coronary vasculitis usually
results in segments of tapered narrowing, coronary ectasia,
and/or aneurysms. Histopathological examination reveals
thrombosis, deposition of immune complexes, infiltration of
lymphocytes/neutrophils, and associated fibrinoid necrosis (64).
A retrospective study assessed findings and outcomes in JSLE
patients who were referred for echocardiography during their
initial presentation for either tachycardia or a newmurmur. Four
patients demonstrated coronary artery dilatation (suggestive
of coronary arteritis) which resolved once JSLE was treated,
leading the authors to conclude that coronary arteritis may be
more common in JSLE than previously appreciated (63). In
a retrospective Taiwanese study looking at cardiopulmonary
involvement in JSLE over a 20-year period, 6/157 patients
exhibited coronary artery abnormalities, including vascular
dilation, aneurysms, vasculitis, and stenosis (67). With SLE itself
being a risk factor for cardiovascular disease, further studies are
required longitudinally evaluating the impact of echocardiogram
surveillance and treatment of coronary vasculitis on long-term
cardiovascular risk.
Aortic Vasculitis
Vasculitis in SLE predominantly affects medium and small
vessels. Aortic (large vessel) involvement has been reported in
small case series and collated within a meta-analysis of 35 cases,
of which 5/35 patients developed SLE in childhood, with aortic
involvement manifesting between the ages of 23 and 38 years
old. Thoracic aneurysms correlated with dissection and cystic
medial degeneration, while abdominal lesions correlated with
atherosclerosis. A total of 21/35 (60%) cases required surgery
and death was observed in 11/35 (31.4%) patients. Thoracic
lesions resulted in higher mortality rates than abdominal lesions
(68). Treatment of aortic vasculitis includes corticosteroids,
cyclophosphamide and blood pressure control. Surgery may be
required in some cases (39, 69). See Table 1 for a summary of
the prevalence of different vasculitic manifestations and the main
treatments used.
SLE VASCULITIS vs.
ANTI-PHOSPHOLIPID SYNDROME
In aSLE patients, APS is associated with cutaneous vasculitis
(30, 70). Differentiating between vasculopathy/thrombosis and
vasculitis in SLE-associated APS can be difficult. However, it
is of utmost importance as treatment approaches are different
(anti-inflammatory treatment for vasculitis vs. anti-thrombotic
Frontiers in Pediatrics | www.frontiersin.org 5 May 2019 | Volume 7 | Article 149
Smith et al. Vasculitis in JSLE
TABLE 1 | Prevalence and treatment of different vasculitc manifestations in JSLE.
Vasculitic manifestation Prevalence in JSLE Usual treatments
Cutaneous vasculitis 12–21.6% (7, 8) • Mild—moderate disease/first line treatments—topical and low-dose systemic corticosteroids,
and/or antimalarial agents.
• More severe disease/second line treatment—high-dose steroids, IVIG, plasmapheresis and/or
cytotoxic treatments (18). Rituximab is an option with otherwise treatment refractory cutaneous
vasculitis (15).
CNS vasculitis NA High-dose glucocorticoids and cyclophosphamide, and may require plasmapheresis and IVIG (40).
PNS vasculitis NA High-dose corticosteroids and cyclophosphamide (43).
Pulmonary vasculitis NA Broad-spectrum antibiotics, high-dose corticosteroids, and/or cyclophosphamide. May need
mechanical ventilation, IVIG, and potentially plasma exchange (46, 47, 50).
Gastrointestinal vasculitis 31.6%* (52) Bowel rest, intravenous corticosteroids, and cyclophosphamide in severe cases (39, 53, 58, 59).
Use of Rituximab has also been described in case series (58).
Aortic vasculitis NA Corticosteroids, cyclophosphamide, and blood pressure control. Surgery may be required in some
cases (39, 69).
*31.6% of all JSLE patients presenting with an acute abdomen (52). JSLE, juvenile systemic lupus erythematosus; NA, not available; IVIG, intravenous immunoglobulin.
therapy for vasculopathy) (71). As mentioned above, histological
assessment of cutaneous lesions can differentiate vasculitis from
cutaneous manifestations of APS. This is particularly relevant in
the context of ischaemic lesions which are difficult to differentiate
clinically. Where biopsy is not practical, it is important to
consider the overall context of the presentation and potential
evidence of other APS-relatedmanifestations such as thrombosis.
In cases with extra-cutaneous evidence of SLE disease flare
or systemic vasculitis, immunosuppressive treatment should be
favored (13).
VASCULITIS IN THE CONTEXT OF
“SLE-LIKE” DISEASE
Primary type-I interferonopathies are a group of Mendelian
disorders that share the upregulation of type-I interferon
signaling as key pathophysiological feature. These monogenic
diseases include (but are not limited to) Aicardi-Goutières
syndrome and syndromic forms of SLE-like disease (72, 73). A
common clinical feature across type I interferonopathies is skin
involvement with chilblain lesions and/or vasculitis as well as
systemic vasculopathy and/or vasculitis, all of which can also
been seen in patients with “classical” JSLE. Though very rare and
not fully reflecting the molecular and clinical phenotype of JSLE,
primary type I interferonopathies and their pathophysiology are
useful “models” for “classical” JSLE, which is also frequently
characterized by type I interferon activation. Furthermore, a
number of other SLE-like conditions, including complement
deficiencies, are characterized by type I interferon responses that
are not primarily caused by mutations in positive or negative
regulators of interferons, but the result of immune complex
accumulation, another key contributor to the pathophysiology of
SLE (74, 75).
Aicardi-Goutières syndrome manifests with progressive
encephalopathy that is associated with calcification of the
basal ganglia, mimicking congenital viral infections (76).
Clinical skin manifestations include chilblain lesions, which
are the name giving feature of familial chilblain Lupus, another
monogenic SLE-like disorder characterized by type I interferon
upregulation (Figures 1D,E). Aicardi-Goutières syndrome,
familial chilblain Lupus and other type I interferonopathies
demonstrate vasculopathy, immune complex deposition, and
lymphocytic vasculitis on skin biopsy (73, 77). Indeed, in severe
cases peripheral vasculopathy can result in atrophy and even
digital auto-amputation in some patients (Figure 1F) (72). This
has particularly been reported in spondyloenchondrodysplasia
with immune dysregulation (SPENCDI), a rare immuno-osseous
dysplasia caused by biallelic mutations in the ACP5 gene (72) and
Stimulator of interferon genes (STING)-associated vasculopathy
with onset in infancy (SAVI) that includes heterozygous
mutations in TMEM173 (78). Both disorders, in addition
to increased activation of type I interferon responses, share
clinical features with “classical” SLE including neurological and
immune manifestations in SPENCDI, and pyrexia, vasculitis,
microthrombotic angiopathy, and interstitial lung disease in
SAVI (78).
CONCLUSIONS
JSLE is a rare, heterogeneous and complex condition. This
translates to difficulty in the recognition and management of
disease, particularly when less common manifestations, such
as vasculitis are involved. Cutaneous is more common than
visceral vasculitis, and more prevalent in JSLE when compared
to adult-onset disease. Reports on visceral vasculitis in JSLE
are limited, which may be a reflection of difficulty in achieving
the diagnosis and differentiating vasculitis from other JSLE-
related complications. Early recognition and treatment of SLE-
associated vasculitis are paramount to optimizing outcomes and
preventing tissue and organ damage. Collaborative approaches
are required to improve our knowledge on the demographics,
clinical presentations, disease courses, and treatment options in
JSLE-associated vasculitis.
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